BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab

Core Viewpoint - BioMarin Pharmaceutical is focusing on business development to strengthen its pipeline and expects to continue pursuing earlier-stage deals while managing debt post-Amicus acquisition [1][7]. Business Development and Growth Strategy - The company has established "multiple pillars of growth," including enzyme therapies and a skeletal conditions business led by Voxzogo, with BMN 333 in development [2][3]. - CEO Alexander Hardy emphasized a strategic refresh that has made business development a key growth driver, evidenced by the Inozyme and pending Amicus acquisitions [3][4]. Competitive Landscape - Voxzogo is facing new FDA-approved competition, but BioMarin anticipates a gradual switching process due to strong adherence and safety data, along with a five-year market lead [5][17]. - The company has prepared for competitive dynamics and believes that the long-term durability and safety of Voxzogo will be crucial in retaining patients [17]. Financial Outlook - BioMarin's 2026 framework anticipates a 3% revenue headwind from the removal of ROCTAVIAN expectations and Kuvan erosion, yet expects core enzyme and skeletal franchises to grow at mid-to-high single digits [6][8]. - The company targets a 40% operating margin in 2026, excluding the impact of Amicus, attributing margin expansion to a refined financial strategy and cost transformation program [14][15]. Pipeline Developments - Key upcoming clinical catalysts include a Phase 3 readout for hypochondroplasia, the weekly-dosed BMN 333 program, and a pediatric Phase 3 readout for BMN 401 in the first half of the year [5][23]. - BioMarin aims for BMN 333 to deliver superior efficacy with a weekly dosing regimen, and the study is powered for a 2.25 cm annualized growth velocity, which is approximately 50% better than Voxzogo [23]. Market Penetration and Expansion - Only about 25% of Voxzogo revenue is generated in the U.S., indicating significant potential for international expansion and deeper market penetration [13]. - The company is focused on increasing its presence in existing markets and launching into new countries to maximize revenue opportunities [13].